Si-bone Stock Fair Value – SI-BONE Reports 30.2% Revenue Increase for Q2 2023 with USD 33.3 Million Total Earnings

August 10, 2023

☀️Earnings Overview

For the second quarter ending June 30 2023, SI-BONE ($NASDAQ:SIBN) reported total revenue of $33.3 million – a 30.2% year-over-year increase. Net income for the same quarter was -$11.2 million, a significant improvement compared to the previous year’s loss of -$18.5 million. The fiscal year 2023 second quarter results were released on August 7 2023.

Analysis – Si-bone Stock Fair Value

GoodWhale has conducted a thorough analysis of SI-BONE‘s wellbeing. Using our proprietary Valuation Line, we have determined that SI-BONE’s fair value is around $24.7. At the time of writing, SI-BONE stock is being traded at $23.4 – despite its true value being 5.4% greater than the current price. This suggests that SI-BONE is being undervalued at the moment and may provide a good investment opportunity for those considering buying in. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • SI-BONE_Reports_30.2_Revenue_Increase_for_Q2_2023_with_USD_33.3_Million_Total_Earnings”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Si-bone. More…

    Total Revenues Net Income Net Margin
    124.4 -47.66 -38.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Si-bone. More…

    Operations Investing Financing
    -38.9 -2.81 2.2
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Si-bone. More…

    Total Assets Total Liabilities Book Value Per Share
    233.82 56.42 4.59
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Si-bone are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    23.0% -35.6%
    FCF Margin ROE ROA
    -39.2% -20.4% -11.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    Its competitors are Heart Tronics Inc, ClearPoint Neuro Inc, Vycor Medical Inc.

    – Heart Tronics Inc ($OTCPK:HRTT)

    Heart Tronics Inc is a medical device company that manufactures and sells cardiac pacemakers and other implantable cardioverter defibrillator devices. As of 2022, the company had a market capitalization of 15.68k and a return on equity of 110.55%. The company’s products are used to treat heart rhythm disorders and are implanted in the chest.

    – ClearPoint Neuro Inc ($NASDAQ:CLPT)

    ClearPoint Neuro Inc, a medical device company, focuses on developing and commercializing technologies to treat neurological disorders. The company offers NeuroBlate System, a laser ablation system that is used to treat various brain disorders; and ClearVec, a cannula system that is used to deliver drugs or other substances to specific areas of the brain. It has a market cap of 229.59M as of 2022 and a Return on Equity of -23.99%.

    – Vycor Medical Inc ($OTCPK:VYCO)

    Vycor Medical Inc is a medical device company that develops, manufactures, and markets minimally invasive products to treat neurological conditions. The company has a market cap of 3.24M as of 2022 and a Return on Equity of 8.79%. Vycor Medical’s products are used by neurosurgeons, neurologists, and other physicians to treat conditions such as brain tumors, cerebral aneurysms, and stroke.


    SI-BONE reported an impressive 30.2% year-over-year increase in total revenue for the second quarter of FY2023, reaching USD 33.3 million. This was accompanied by a net income of -11.2 million, significantly narrowed from its -18.5 million loss from the corresponding period in the previous year. This strong performance suggests that SI-BONE is recovering from its earlier financial woes and is now on a path of growth and recovery, making it an attractive investment opportunity.

    Recent Posts

    Leave a Comment